Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-12,500
Closed -$850K 1091
2023
Q1
$850K Buy
12,500
+1,100
+10% +$89K ﹤0.01% 891
2022
Q4
$811K Buy
+11,400
New +$777K ﹤0.01% 920
2022
Q3
Sell
-3,500
Closed -$234K 1142
2022
Q2
$234K Hold
3,500
﹤0.01% 1060
2022
Q1
$252K Buy
+3,500
New +$287K ﹤0.01% 1132
2019
Q1
Sell
-11,400
Closed -$282K 1318
2018
Q4
$282K Sell
11,400
-3,400
-23% -$83.4K ﹤0.01% 1183
2018
Q3
$466K Sell
14,800
-17,000
-53% -$613K ﹤0.01% 1156
2018
Q2
$1.19M Buy
+31,800
New +$1.24M ﹤0.01% 966

Other funds holding BXC

Axa's BXC Position: Q2 2023 in Review

Axa sold out of BlueLinx (BXC) in Q2 2023, closing a stake of 12,500 shares — an estimated $850K sold.

Axa first reported a position in BXC in Q2 2018 and held it in 7 quarters. The position peaked at $1.19M in Q2 2018. 168 funds tracked by Wall St. Rank hold BXC as of Q2 2023.

  • Axa reported no remaining BlueLinx position as of Q2 2023 after selling out during the quarter.
  • Axa sold 12,500 BlueLinx shares in Q2 2023, an estimated $850K.
  • Axa first reported a position in BlueLinx in Q2 2018 and held it in 7 quarters.
  • Axa's BlueLinx position peaked at $1.19M in Q2 2018.
  • 168 funds tracked by Wall St. Rank held BlueLinx as of Q2 2023.

Based on Axa's 13F filing for Q2 2023, filed 14 Aug 2023.